Navigation Links
NOVAVAX Reports Third Quarter 2010 Financial Results
Date:11/5/2010

statements contained in this release.  Factors that may cause actual results to differ materially from the results discussed in the forward-looking statements or historical experience include, among other things, the following: our ability to progress any product candidates into pre-clinical or clinical trials; the scope, initiation, rate and progress of our pre-clinical studies and clinical trials and other research and development activities; clinical trial results; even with positive data from pre-clinical studies or clinical trials, the product candidate may not prove to be safe and efficacious; decisions by regulatory agencies may delay or prevent our development programs or increase the costs of such programs; regulatory approval is needed before any we can initiate clinical trials on our vaccines; regulatory approval is needed before any vaccines can be sold in or outside the United States and, to date, no governmental authority has approved any of our vaccine candidates for sale; influenza is seasonal in nature, and if approval or commercial launch after approval is not timely in relation to the influenza season, we may not be able to manufacture or sell our influenza vaccines on terms favorable to us until the next influenza season, if at all; RSV is a difficult disease to prevent and there is significant activity by many companies toward the development of a suitable vaccine; we have not manufactured any of our vaccine candidates at a commercial level; we utilize a unique manufacturing process and the scale-up of that process may prove difficult and/or costly; our dependence on third parties to manufacture and distribute our vaccines; risks associated with conducting business outside of the United States; the cost and our ability of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights; competition for clinical resources and patient enrollment from drug candidates in developm
'/>"/>

SOURCE Novavax, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Novavax to Report Third Quarter 2010 Financial Results on November 5, 2010
2. NOVAVAX to Present at BIO Investor Forum
3. NOVAVAX to Present at Stifel Nicolaus Conference
4. NOVAVAX Endorses New U.S. Initiatives to Develop Medical Countermeasures
5. NOVAVAX Announces Issuance of Key U.S. Patent for Influenza Virus-Like Particle (VLP) Vaccines
6. Novavax CEO to Present at Phacilitate Vaccine Forum Barcelona 2010
7. Novavaxs Seasonal Influenza VLP Vaccine Candidate Shows Positive Results in a Phase II Clinical Trial in Older Adults
8. NOVAVAX Reports Fourth Quarter and 2009 Year-End Financial Results
9. NOVAVAX to Present at 22nd Annual ROTH OC Growth Stock Conference
10. NOVAVAX to Present at Cowen and Companys 30th Annual Health Care Conference
11. NOVAVAX Reports Additional Positive Data from Its Trivalent Seasonal Influenza (VLP) Vaccine Clinical Study in Healthy Adults
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014  Zafgen, Inc., ... unmet needs of severely obese patients, today announced ... beloranib, a selective inhibitor of methionine aminopeptidase 2 ... severe form of genetic obesity.  These results showed ... composition, including reductions in body fat content and ...
(Date:1/14/2014)... HAMILTON, N.J. , Jan. 14, 2014 ... partnering event for buyers and sellers of high-value chemistry, ... annual conference at the Miami Beach ... http://photos.prnewswire.com/prnh/20131028/NY05330LOGO-a ) More than 3,500 ... companies will take part in the conference, which includes ...
(Date:1/14/2014)... Emergency Critical Care, a LifeCentre partner practice, located at 165 Fort ... first in Loudoun County to receive a ... M. Barnes , Medical Director, is a well-seasoned veterinarian of more ... , are avid scuba divers. "As altitude skiers and hikers, we ... states Dr Barnes. She goes on to state "my wish list ...
Breaking Medicine Technology:Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4Media Advisory: InformEx 2014 Events & Speaker Lineup for 30th Edition Conference in Miami Beach 2Hyperbaric Veterinary Medicine (hvm) Announces Animal Emergency Critical Care Installs A Small Animal Hyperbaric Chamber 2
... Mich., Oct. 29 Perrigo Company (Nasdaq: PRGO;TASE) today ... dividend of $0.0625 per share, payable on December 15, ... The new quarterly dividend of $0.0625 per share ... paid in the last four quarters. , Perrigo ...
... HONOLULU, Oct. 29 /PRNewswire-FirstCall/ -- ... ), the global specialty biopharmaceutical company, announced today that it ... treatments, INTUNIV (TM) (guanfacine) Extended Release Tablets, ... and Daytrana ®( ) (methylphenidate transdermal system) ...
Cached Medicine Technology:Shire to Present Important Study Findings on its ADHD Treatments at a Major Psychiatric Meeting on October 29 and 30 2Shire to Present Important Study Findings on its ADHD Treatments at a Major Psychiatric Meeting on October 29 and 30 3Shire to Present Important Study Findings on its ADHD Treatments at a Major Psychiatric Meeting on October 29 and 30 4Shire to Present Important Study Findings on its ADHD Treatments at a Major Psychiatric Meeting on October 29 and 30 5Shire to Present Important Study Findings on its ADHD Treatments at a Major Psychiatric Meeting on October 29 and 30 6Shire to Present Important Study Findings on its ADHD Treatments at a Major Psychiatric Meeting on October 29 and 30 7Shire to Present Important Study Findings on its ADHD Treatments at a Major Psychiatric Meeting on October 29 and 30 8Shire to Present Important Study Findings on its ADHD Treatments at a Major Psychiatric Meeting on October 29 and 30 9
(Date:4/14/2014)... treat children with uncomplicated acute appendicitis is a reasonable ... fewer missed school days, according to a pilot study. ... Hospital and published online April 12 in the ... the first prospective study on nonoperative management of acute ... , Researchers enrolled 77 patients age 7 to 17 ...
(Date:4/14/2014)... 2014, Perth, Australia. Drug discovery company Proteomics International ... of a companion diagnostic (CDx) test with the ... The research team authenticated the panel of biomarkers ... samples. Seven biomarkers were validated at high stringency ... The mass spectrometry data was then cross-validated using ...
(Date:4/14/2014)... 2014) When it comes to the cost and ... Patients get the best care when they are treated ... extensive experience in their current job, according to a ... and Columbia Business School. The study was published in ... Applied Economics . , The review of more ...
(Date:4/13/2014)... STANFORD, Calif. A low-cost empowerment program for ... and sexual harassment of these girls, who live ... and are frequently attacked, a large new study ... Stanford University School of Medicine, Lucile Packard Children,s ... No Worldwide, validated the program,s effectiveness in combating ...
(Date:4/11/2014)... the processes that control brain cell production could pave ... brain-related disorders. , Scientists have gained new understanding of ... how and when nerve and brain cells are formed ... and keeps it healthy. Their findings could help explain ... which is a fundamental characteristic of many diseases including ...
Breaking Medicine News(10 mins):Health News:Antibiotics alone are a successful treatment for uncomplicated acute appendicitis in kids 2Health News:Antibiotics alone are a successful treatment for uncomplicated acute appendicitis in kids 3Health News:Longer nurse tenure on hospital units leads to higher quality care 2Health News:Empowerment program greatly decreases incidence of rape, Stanford/Packard-led study finds 2Health News:Empowerment program greatly decreases incidence of rape, Stanford/Packard-led study finds 3Health News:Empowerment program greatly decreases incidence of rape, Stanford/Packard-led study finds 4
... March 23 (HealthDay News) -- A new study helps ... drug therapy. Researchers at the Massachusetts General Hospital ... non-small cell lung cancer, the leading cause of cancer ... with resistance. They also confirmed resistance-related genetic changes ...
... Concordia University have pioneered a computer-based method to detect ... that may open a window on the brain,s electrical ... Detection of Epileptic Seizures," presented at the annual meeting ... the very successful application of this new seizure-detection method. ...
... in French . The human brain loses 5 ... 90 years old. While some cells are lost, the brain is ... results of her most recent clinical study published today in the ... Sylvie Belleville, PhD in neuropsychology, the principal author of this study ...
... will convene in Chicago this week to present new ... detect, treat, prevent and cure osteoarthritis (OA), which affects ... the Segal North American Osteoarthritis Workshop (SNOW) on March ... as those that follow joint trauma, obesity and the ...
... who take statin drugs commonly used to lower cholesterol ... their cancer return than patients who do not take ... March issue of the International Journal of Radiation OncologyBiologyPhysics, ... Oncology (ASTRO). , In the study, 1,681 men with ...
... March 22 (HealthDay News) -- Trauma injury patients who arrive ... no more likely to die than those who arrive on ... contrast with previous research that said patients with health emergencies ... they arrive at the hospital at night or on weekends. ...
Cached Medicine News:Health News:Lung Cancer Evolves With Treatment, Study Finds 2Health News:New way to detect epileptic seizures 2Health News:Subjects at risk of Alzheimer's may now be able to delay the onset of their first symptoms 2Health News:Researchers explore new treatments to end OA 2Health News:Trauma Patients Seem More Likely to Survive on Weekends 2
Flexilog custom medical carts are configured to suite the requirements of FLEXILOG motility system users. With locking wheels and storage drawers, our carts are suitable for any care provider in any ...
... Calibration kit for convenient pH catheter calibration., ... to any procedure. The Alpine Calibration kit ... distilled water for your convenience. Simply cut ... your catheters to soak. No measuring or pouring! ...
Bravo Tubing/Filter Supplies (Ten tubing sets, ten filters)...
Bravo pH capsule with delivery system....
Medicine Products: